Half of patients who die from prostate cancer have metastases at diagnosis
the ONA take:
According to a new study published in the journal Prostate Cancer & Prostatic Diseases, researchers sought to determine which types of patients die from prostate cancer in the modern era.
The researchers identified 190 men with metastatic castration-resistant prostate cancer (CRPC) treated between 2008 and 2011 and analyzed the characteristics of the 113 patients who died as a result of prostate cancer.
Of the 113 patients, 56% had identifiable metastases at the time of diagnosis. Of those, 67% had bone metastases, 111% had visceral metastases, and 43% had lymph node metastases. The median time to developing CRPC was 16 months and the median overall survival was approximately 5.2 years.
Among patients who died from prostate cancer, 46% of those initially diagnosed with localized disease had T stage ≥3 and 38% had a Gleason score ≥8. Overall, 26% had a Gleason score ≤6 and 64% were classified as having high-risk prostate cancer. The median overall survival was found to be 8.8 years.
The findings suggest that among those who die from prostate cancer, about half have detectable metastases at diagnosis. Therefore, the researchers recommend that more future studies should be conducted in patients with newly diagnosed metastatic prostate cancer.
researchers sought to determine which types of patients die from prostate cancer in the modern era.
The authors used two monthly curated databases of patients with castration–resistant prostate cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era. In the modern era, approximately half of the patients who die from CaP have metastases at diagnosis.
The paradigm of progression from localized disease to metastasis and eventually death is only represented in the other half, although possible initial screening and staging errors ought to be taken into consideration. More efforts are needed to conduct trials in patients with newly diagnosed metastatic CaP.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Cervical Cancer Outcomes Comparable With Adjuvant Chemotherapy, Chemoradiotherapy
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Risk for Long-Term Cardiovascular Disease Increased for Endometrial Cancer Survivors
- Mitomycin Extravasation Protocol
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
- Internal Benchmarking Improves Nurse Workflow, Staffing in Radiation Oncology
- Flu, Pneumonia Vaccination Rates in Cancer Patients Improved With Nurse-Driven Protocol
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|